We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Apricus Biosciences has cut 30 percent of its workforce — including part of its executive team — following an unsuccessful Phase 2b trial evaluating fispemifene in men with secondary hypogonadism and sexual dysfunction. Read More
A final batch of biomedical innovation bills sailed through markup during a meeting of the Senate HELP Committee Wednesday, as lawmakers work toward passing a companion to the House’s 21st Century Cures Act this session. Read More
The European Medicines Agency is recommending that sponsors use clinical trial information from adults to support the development of therapies for children. Read More